Exelixis Quarterly Income Statement
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis revenue and earnings
In the quarter ended Jul 3, 2026, Exelixis generated $628.7 million in revenue, up 10.6% from the same quarter a year earlier. Net income was $212.1 million (+14.7% year over year), for a net margin of 33.7% versus a median of 32.5% in the prior 5 quarters. Gross margin was 96.7% (up from 96.6%) and operating margin 39.5%.
Diluted earnings per share came in at $0.82, up from $0.65.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis income statement (quarterly)
| Quarter (USD) | Q2 20262026-07-03 | Q1 20262026-04-03 | Q4 20252026-01-02 | Q3 20252025-10-03 | Q2 20252025-07-04 | Q1 20252025-04-04 | Q4 20242025-01-03 | Q3 20242024-09-27 | Q2 20242024-06-28 | Q1 20242024-03-29 | Q4 20232023-12-29 | Q3 20232023-09-29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 628.69M | 610.81M | 598.66M | 597.75M | 568.26M | 555.45M | 566.75M | 539.54M | 637.18M | 425.23M | 479.65M | 471.92M |
| Revenue growth (YoY) | +10.63% | +9.97% | +5.63% | +10.79% | -10.82% | +30.62% | +18.16% | +14.33% | +35.61% | +4.02% | +13.15% | +14.62% |
| Cost of Revenue | 20.66M | 19.95M | 26.48M | 18.57M | 19.47M | 19.17M | 19.96M | 17.33M | 17.67M | 21.26M | 21.75M | 18.77M |
| Gross Profit | 608.03M | 590.86M | 572.18M | 579.18M | 548.79M | 536.27M | 546.79M | 522.21M | 619.51M | 403.97M | 457.90M | 453.15M |
| Operating Expenses | 359.62M | 339.52M | 336.97M | 342.64M | 335.21M | 349.42M | 383.58M | 386.14M | 343.64M | 374.51M | 376.11M | 470.73M |
| Research & Development | 211.99M | 199.92M | 213.25M | 199.16M | 200.36M | 212.23M | 249.00M | 222.57M | 211.15M | 227.69M | 244.67M | 332.58M |
| Selling, General & Admin | 147.63M | 139.60M | 123.02M | 123.66M | 134.86M | 137.18M | 134.33M | 111.80M | 132.01M | 113.98M | 131.44M | 138.14M |
| Operating Income | 248.41M | 251.34M | 235.22M | 236.54M | 213.58M | 186.86M | 163.21M | 136.07M | 275.87M | 29.46M | 81.79M | -17.58M |
| Other Income (Expense) | 54.00K | 219.00K | 46.00K | -49.00K | 50.00K | -245.00K | 272.00K | -29.00K | -287.00K | -89.00K | -137.00K | 289.00K |
| Income Tax | 50.63M | 57.22M | 8.16M | 58.84M | 45.57M | 46.07M | 44.91M | 36.78M | 66.73M | 11.95M | 17.52M | 4.78M |
| Net Income | 212.05M | 210.47M | 244.53M | 193.58M | 184.85M | 159.62M | 139.86M | 117.97M | 226.12M | 37.32M | 85.52M | 1.04M |
| Net Income growth (YoY) | +14.72% | +31.86% | +74.84% | +64.09% | -18.25% | +327.73% | +63.55% | +11232.66% | +178.54% | -6.77% | — | -98.58% |
| EPS (Basic) | 0.85 | 0.81 | 0.91 | 0.72 | 0.68 | 0.57 | 0.49 | 0.41 | 0.78 | 0.12 | 0.28 | 0.00 |
| EPS (Diluted) | 0.82 | 0.79 | 0.89 | 0.69 | 0.65 | 0.55 | 0.47 | 0.40 | 0.77 | 0.12 | 0.28 | 0.00 |
| Shares Outstanding (Basic) | 250.81M | 258.33M | — | 268.42M | 272.58M | 278.80M | — | 285.62M | 289.22M | 300.76M | — | 315.50M |
| Shares Outstanding (Diluted) | 259.68M | 267.32M | — | 278.54M | 284.39M | 288.18M | — | 291.48M | 293.97M | 305.53M | — | 319.25M |
| EBITDA | 255.40M | 258.29M | 242.16M | 243.96M | 220.92M | 194.20M | 170.85M | 143.53M | 283.20M | 35.84M | 88.31M | -11.29M |
| Gross Margin | 96.71% | 96.73% | 95.58% | 96.89% | 96.57% | 96.55% | 96.48% | 96.79% | 97.23% | 95.00% | 95.46% | 96.02% |
| Operating Margin | 39.51% | 41.15% | 39.29% | 39.57% | 37.58% | 33.64% | 28.80% | 25.22% | 43.30% | 6.93% | 17.05% | -3.73% |
| Net Margin | 33.73% | 34.46% | 40.85% | 32.38% | 32.53% | 28.74% | 24.68% | 21.87% | 35.49% | 8.78% | 17.83% | 22.00% |
This table shows 12 quarterly periods of Exelixis's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow EXEL's reporting calendar. What is a income statement?